Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 55 publications.

Wesselink AK, Lovett SM, Weinberg J, Geller RJ, Wang TR, Regan AK, Willis MD, Perkins RB, Yland JJ, Koenig MR, Rothman KJ, Hatch EE, Wise LA. COVID-19 vaccination and menstrual cycle characteristics: a prospective cohort study. Vaccine. 2023 Jun 29;41(29):4327-34. doi: 10.1016/j.vaccine.2023.06.012

Talbird SE, Anderson SA, Nossov M, Beattie N, Rak AT, Diaz-Mitoma F. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis b in adults in the United States. Vaccine. 2023 May 26;41(23):3506-17. doi: 10.1016/j.vaccine.2023.04.022

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036

Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002

Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov 1;22(17):1121-33. doi: 10.2217/pgs-2021-0089

Carrico J, Talbird SE, La EM, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021 Aug 23;39(36):5187-97. doi: 10.1016/j.vaccine.2021.07.029

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021 May 6;39(19):2660-7. doi: 10.1016/j.vaccine.2021.03.071

Guzman-Holst A, Luna-Casas G, Cervantes-Apolinar MY, Huerta-Garcia GC, Juliao P, Sanchez-Gonzalez G. Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: an ecological database study with time-series analysis. Vaccine. 2021 Apr 15;39(16):2311-8. doi: 10.1016/j.vaccine.2021.02.038

Bell CF, Lau M, Lee M, Poulos C. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. Clin Rheumatol. 2021 Feb;40(2):581-90. doi: 10.1007/s10067-020-05226-w

Dong OM, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program. Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173

Juliao P, Abadia I, Welby S, Wery S, Wong D, De Leon T, DeAntonio R, Naranjo L, Guignard A, Marano C. Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine. 2021 Jan 3;39(1):26-34. doi: 10.1016/j.vaccine.2020.11.030

Carrasquilla G, Porras A, Martinez S, DeAntonio R, Devadiga R, Caceres DC, Juliao P. Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia. Vaccine. 2020 Oct 27;38(46):7384-92. doi: 10.1016/j.vaccine.2020.07.046

Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O’Neil C, Weber DJ, Butler AM. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Vaccine. 2020 Jun 6;38(33):5178-86. doi: 10.1016/j.vaccine.2020.06.020

Orta OR, Hatch EE, Regan AK, Perkins R, Wesselink AK, Willis SK, Mikkelsen EM, Rothman KJ, Wise LA. A prospective study of influenza vaccination and time to pregnancy. Vaccine. 2020 Jun 2;38(27):4246-51. doi: 10.1016/j.vaccine.2020.04.054

Xie J, Yong ASM, Waweru C, Sorof T-A, Goyal RK, Davis KL, Hillmen P. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the United Kingdom. Poster presented at the 2020 British Society for Haematology 60th Annual Scientific Meeting (Conference cancelled); April 2020. Birmingham, United Kingdom. [abstract] Br J Haematol. 2020 Apr; 189((Suppl.1)):221.

Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C. The adult vaccination landscape in the United States during the Affordable Care Act era: results from a large retrospective database analysis. Vaccine. 2020 Mar;38(14):2984-94. doi: 10.1016/j.vaccine.2020.02.057

Baker MA, Jankosky C, Yih WK, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, DeLuccia S, Lin ND, McMahill-Walraven CN, Menschik D, Selvan MS, Selvam N, Chen Tilney R, Zichittella L, Lee GM, Kawai AT. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Vaccine. 2020 Feb 24;38(9):2166-71. doi: 10.1016/j.vaccine.2020.01.046

Guzman-Holst A, DeAntonio R, Prado-Cohrs D, Juliao P. Barriers to vaccination in Latin America: a systematic literature review. Vaccine. 2020 Jan 16;38(3):470-81. doi: 10.1016/j.vaccine.2019.10.088

Suzuki O, Dong OM, Howard RM, Wiltshire T. Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. Pharmacogenomics. 2019 Sep;20(14):1005-20. doi: 10.2217/pgs-2019-0057

Kawai AT, Martin D, Henrickson SE, Goff A, Reidy M, Santiago D, Selvan N, McMahill-Walraven C, Lee GM. Validation of febrile seizures identified in the Sentinel Post-Licensure Rapid Immunization Safety Monitoring Program. Vaccine. 2019 Jul 9;37(30):4172-6. doi: 10.1016/j.vaccine.2019.05.042.

Layton JB, Butler AM, Brookhart MA, Panozzo CA. Variation in rotavirus vaccination coding in state US medicaid data. Vaccine. 2019 May 16;37(22):2892-5. doi: 10.1016/j.vaccine.2019.02.074

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine. 2019 Feb 21;37(9):1235-44. doi: 10.1016/j.vaccine.2018.11.079

Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019 Feb;184(4):660-3. doi: 10.1111/bjh.15149

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson B, Levin M. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 Oct 29;36(45):6810-8. doi: 10.1016/j.vaccine.2018.08.080

Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: a vaccine safety datalink study. Vaccine. 2018 Oct 1;36(41):6111-6. doi: 10.1016/j.vaccine.2018.08.074

McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018 Oct 1;36(41):6087-94. doi: 10.1016/j.vaccine.2018.08.079

Poulos C, Standaert B, Sloesen B, Stryjewska I, Janitsary A, Hauber B. Preferences for vaccines against children's diarrheal illness among mothers in Poland and Hungary. Vaccine. 2018 Sep 25;36(40):6022-9. doi: 10.1016/j.vaccine.2018.08.001

Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005

Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 Jun 1;19(9):771-82. doi: 10.2217/pgs-2018-0049

Wiltshire T, Dong OM. Clinical pharmacogenetics: how do we ensure a favorable future for patients? Pharmacogenomics. 2018 Apr;19(6):553-62. doi: 10.2217/pgs-2017-0192

Poulos C, Curran D, Anastassopoulou A, De Moerlooze L. German travelers' preferences for travel vaccines assessed by a discrete choice experiment. Vaccine. 2018 Feb 8;36(7):969-78.

Rouse CE, Eckert LO, Babarinsa I, Fay E, Gupta M, Harrison MS, Kawai AT, Kharbanda EO, Kucuku M, Meller L, Mallett Moore T, Subelj M, Kochhar S, Tavares-Da-Silva F, GAIA Abortion Work Group, Brighton Collaboration Abortion Working Group. Spontaneous abortion and ectopic pregnancy: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data - Commentary. Vaccine. 2017 Dec 4;35(48 Pt A):6563-74. doi: 10.1016/j.vaccine.2017.01.047

Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017 Aug;18(2):1155-66. doi: 10.2217/pgs-2017-0075

Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath LJ, Becker-Dreps S. Prenatal Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 2017 Jul 24;35(33):4072-8. doi: 10.1016/j.vaccine.2017.06.071

DaSilva T, Gonik B, Mcmillan M, Keech C, Dellicour S, Bhange S, Tila M, Harper DM, Woods C, Kawai AT, Kochhar S, Munoz FM, Brighton Collaboration Stillbirth Working Group. Stillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2016 Dec 1;34(49):6057-68. doi: 10.1016/j.vaccine.2016.03.044

DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, Joshi J, Oneko M, Rose AE, Dolk H, Trotta F, Spiegel H, Tomczyk S, Shrestha A, Kochhar S, Kharbanda EO, Brighton Collaboration Congenital Anomalies Working Group. Congenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016 Dec 1;34(49):6015-26. doi: 10.1016/j.vaccine.2016.03.047

Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895

Kurosky SK, Davis KL, Krishnarajah G. Completion and compliance of childhood vaccinations in the United States. Vaccine. 2016 Jan 12;34(3):387-94. doi: 10.1016/j.vaccine.2015.11.011

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399

Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine. 2015 Mar 10;33(11):1313-6. doi: 10.1016/j.vaccine.2015.01.069

Thyagarajan (Hoffman) V, Su S, Gee J, Duffy J, McCarthy NL, Chan KA, Weintraub ES, Lin ND. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. Vaccine. 2013 Dec 5;31(50):5997-6002. doi: 10.1016/j.vaccine.2013.10.026

McCarthy NL, Gee J, Lin ND, Thyagarajan (Hoffman) V, Pan Y, Su S, Turnbull B, Chan KA, Weintraub E. Evaluating the safety of influenza vaccine using a claims-based health system. Vaccine. 2013 Dec 5;31(50):5975-82.

Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375

Karve S, Meier G, Davis KL, Misurski DA, Wang CC. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013;31(33):3370-88.

Tse (Kawai) A, Tseng HF, Greene SK, Vellozzi C, Lee GM, VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012 Mar 2;30(11):2024-31. doi: 10.1016/j.vaccine.2012.01.027

Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR. Reply to Strutton et al.: response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. Vaccine. 2011 Oct 1;29(44):7591-2.

Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010 Nov 19;28(Suppl 6):G14-22.

Talbird SE, Taylor TN, Knoll S, Frostad CR, Marti SG. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov 19;28(Suppl 6):G23-9.

Talbird SE, Ismaila AS, Taylor TN. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 2010 Nov 19;28(Suppl 6):G3-G13.

Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010 Nov 19;28(Suppl 6):G30-8.